Peer Review History
| Original SubmissionApril 26, 2020 |
|---|
|
PONE-D-20-12100 Characterizing the transport and utilization of the neurotransmitter GABA in the bacterial pathogen <brucella abortus=""> PLOS ONE Dear Dr. Caswell, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.</brucella> Please consider the comments of the reviewers to improve the manuscript. Please submit your revised manuscript by Jul 20 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols We look forward to receiving your revised manuscript. Kind regards, Axel Cloeckaert Academic Editor PLOS ONE Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 2. In your Methods, please include full details of animal care and housing, including details of the monitoring of animals for adverse clinical signs. 3. We note that you have stated that you will provide repository information for your data at acceptance. Should your manuscript be accepted for publication, we will hold it until you provide the relevant accession numbers or DOIs necessary to access your data. If you wish to make changes to your Data Availability statement, please describe these changes in your cover letter and we will update your Data Availability statement to reflect the information you provide. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Partly Reviewer #2: Yes Reviewer #3: Yes ********** 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: I Don't Know Reviewer #2: Yes Reviewer #3: Yes ********** 3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: No Reviewer #3: Yes ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes ********** 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: The manuscript submitted by Budnick et al describes the efforts to characterized the putative role in GABA transport of two of the target transporter systems of sRNAs AbcR1/2, found previously by Dr. Caswell's group. By measuring accumulation of radioactive H3-GABA, the authors are able to provide some evidence of the role of one of them as a GABA transporter. A drawing of the BAB1_1792-BAB1_1799 and BAB2_0876-BAB2_0879 transport systems, or a description of the role of its different components would be helpful to understand the experiments. Are the deleted proteins structural, crucial components, or just accessory ones? Similarly, a map of both locus would be helpful to know if the authors have deleted two or three genes, as it is not unusual in Brucella genomes to have non consecutive numbering. Figure 7 shows the locus bab2_0876-bab2_0879 along with the putative role of each protein, but this is too late in the manuscript and I think the reader would benefit from having this (or at least some of this) information up front, and included in the body of the manuscript. Mention more clearly which strains were constructed for this work, as in page 11 is stated “Deletion strains of bab2_0612, bab1_1792-bab1_1794, and bab2_0879 were either constructed or utilized from previous studies”. As only deletion strains bab1_1792 and bab1_1794 are described in M&M, we have to assume that the other two strains were constructed in a previous study that should be referenced. This brings us to a shocking point, why have the authors mutated bab2_0612?? They do not mention anything about this strain, however it shows a 20% decrease in GABA transport.. Is it controlled by any of these sRNAs? Is it a control transporter? Without this information it’s impossible to understand its role, nor the role of the second transporter that also shows another 20% decrease in GABA transport. Regarding the deletion, and going back to the first comment, the reader does not get any information about the size or content of the region deleted, or the function of the affected proteins, until line 370, in the Discussion section, where the homology of one of the proteins is mentioned. The 3H-GABA uptake assays is normalized to the observed level in GMM(-Glu). This should be explained in M&M, or in the Figure legend, rather than at the y axis of Figure 1. Same applies for Figure 2. Regarding the physiological role of GABA transport, the authors observe that GABA is not used as a nitrogen or carbon source, and the transcriptional changes observed are anecdotal. Nor do they observe any change in virulence either in peritoneal macrophages or in the oral infection mouse model, reinforcing previous results from the group that these mutants do not show a different virulence levels in the intraperitoneal infection mouse model. But then they engaged in a not very convincing discussion about the possible role of these systems in virulence in B. abortus, citing some work done in B. melitensis and B. suis. It’s difficult with the data provided by the authors to gauge if this information is anything more than anecdotal. For example, how many nonsynonymous mutations are between the 16M and M5 B. melitensis strains? There are extensive areas of insertion and deletion between these two strains as to point out this particular change as important for the virulence. As for the attenuated phenotype reported by Delrue, the authors do not know the nature of the mutations described, and whether they could induce (for example) downstream effects. The authors should ponder if the level of evidence gathered so far merits further study of the putative role of gtsA in B. abortus, something that for this reviewer is in this moment doubtful. The nomenclature bab_rs30470 is mentioned for the first time in page 16, without any explanation. The same way the authors mention that Agrobacterium fabrum was formerly known as Agrobacterium tumefaciens in page 4 (by the way, a reference to the change would be handy), the authors should use the old or the new nomenclature for the genes, or explain it at least the origin of this change. Consistent nomenclature: The authors use B. abortus 2308, and Brucella melitensis biovar abortus 2308. This could be confusing for general readers outside the Brucella field, so please use consistent nomenclature. Line 373. The results from Figure 4 merit a more extensive discussion. To say that GABA transport is mediated only by bab2_0879 is not correct. First, it should be mentioned the whole transporter, nor just the mutated gene that interrupts the system. And also the 20% (statistically significant, by the way) decrease in GABA transport observed when either bab2_0612 or bab1_1792-bab1_1794 are mutated should be considered and discussed. Have the authors tested if B. abortus 2308 AbcR1 or AbcR2 single mutants show an inhibited GABA transport (just to see if in any occasion these sRNAs are not redundant…) Minor points Use B. abortus after the first time Brucella abortus is used First three letters of restriction enzymes in italics Keywords: amino Reviewer #2: This manuscript describes the transport of GABA in the class III pathogen Brucella abortus. The transporter is identified and shown to be specific to GABA compared to 20 aminoacids. First investigations on the possible function of this transport system and the impact of GABA transport on the transcriptiome are reported here. This is an interesting, rigorous and well controlled study. I only have (very) minor comments. - line 76 : it seems that reference should be [16] and not [15] - line 108 : "by adaptation" to what? intracellular conditions? [25] maybe specify - line 126 : add one or more references after "GAD system" - line 130 : why does the absence of a functional GAD excludes the possibility of GABA utilization? It seems that GabT and GabD would be sufficient to utilize GABA, if they are active of course. - lines 187-191 : the authors comment on Cys and Lys but not the other aminoacids (Asn, Met,Trp and Val) that are also significantly different from the control. I agree that differences are very small and probably negligible - line 235 : add a reference after "regulated by AbcR1 and AbcR2" - line 243 : since a function is found for BAB2_0879, I would suggest to add a sentence to rename BAB2_0879 as gtsA at this place of the manuscript - line 268-270 : the gtsA mutation does not impact the ability to survive and replicate in macrophages, but if glutamate is present in the culture medium of the macrophages, it is normal that the GABA transport system is not active (according to data in Fig. 1). If it is correct, this should be discussed - lines 337-343 : if it is allowed by the journal, I would provide the mRNA quantification per gene as supplementary data - line 359 : in the legend of Figure 7, I would clearly indicate which operon (bra or gts) is used for calculating the percentages of identity (from the text, it seems to be gts) - since it is reported that gad gene may be inactivated by point or frame-shift mutations, it could be interesting to analyse the conservation of the gts, gabT and gabD genes in the different Brucella species. - line 427 : for the information to these authors, the Delrue/Letesson lab and A. Dricot in particular were using exclusively the BALB/c mice, intraperiotoneal infections and CFU countings in the spleen (at 1, 4 or 8 weeks post-infection). Since it is not published (A. Dricot never finished her PhD thesis), I would leave the text as it is. -line 434 : mouse strain is important but the route of infection is also crucial and should be mentionned here - line 468 : if I understand correctly a single deletion strain is generated, in which ORFs bab1_1794 to bab1_1792 are deleted. Thus the sentence should be clarified. Also, a reference should be given for the deletion strains of bab2_0612 and bab2_0879 (and indicate if they are also unmarked and nonpolar deletion strains). - line 501 : how was radioactivity of the filter measured? - line 521 : is it L-GABA? I did not see an asymmetrical carbon the GABA structure - line 548 : remove the sentence starting with "The FASTQ files"? - line 567 : how were brucellae opsonized? - Discussion : is there any comment to make, related to neurobrucellosis? Reviewer #3: The paper by Budnick et. al. describes the identification of a GABA transporter in the zoonotic pathogen Brucella abortus. The authors show that B. abortus is able to transport GABA, that this transport is not inhibited by the presence of other amino acids and that GABA is not used neither as a nitrogen nor as a carbon source. The authors additionally demonstrate that the small RNAs AbcR1 and AbcR2 negatively regulate the transport of GABA and identify the transporter (Bab2_0879) as the responsible for the transport. A null mutation in this gene did not affect the intracellular replication in macrophages or the virulence in mice indicating that the transport is not necessary for the pathogenesis of the bacterium. The paper is clear and the data supports the conclusions that are, mainly, negative: transport of GABA is not inhibited by other amino acids, it is not utilized as a carbon or nitrogen source, it is not required for virulence and does not affect the transcriptome of the bacterium. Despite this, the data presented clearly demonstrate that GABA is transported and that the transported is Bab2_0879. The only criticisms I have is that in the discussion (lines 438 to 449) the authors argue that it could be that the transport of GABA could work as a way to mask the induction of GABA in the macrophages altering the maturation of the phagosome. If this would be the case a difference in macrophage survival should have been observed in the Bab2_0879 mutant. I recommend this speculation should be deleted. ********** 6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: No Reviewer #3: No [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. |
| Revision 1 |
|
Characterizing the transport and utilization of the neurotransmitter GABA in the bacterial pathogen <brucella abortus=""> PONE-D-20-12100R1</brucella> Dear Dr. Caswell, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Axel Cloeckaert Academic Editor PLOS ONE Additional Editor Comments (optional): Reviewers' comments: |
| Formally Accepted |
|
PONE-D-20-12100R1 Characterizing the transport and utilization of the neurotransmitter GABA in the bacterial pathogen <Brucella abortus> Dear Dr. Caswell: I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org. If we can help with anything else, please email us at plosone@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Axel Cloeckaert Academic Editor PLOS ONE |
Open letter on the publication of peer review reports
PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.
We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.
Learn more at ASAPbio .